This editorial summarises important findings from the PARADIGM-HF study. PARADIGM-HF indicated that the angiotensin receptorneprilysin inhibitor, LCZ696, is superior to enalapril in reducing the risks of cardiovascular death and of hospitalisation for heart failure in patients with heart failure and reduced ejection fraction.
PARADIGM-HF
In the randomised, double-blind, multicentre, international trial PARADIGM-HF (ClinicalTrials.gov number NCT01035255), 8, 442 patients with HF and a left ventricular ejection fraction ≤40%, in New York Heart Association (NYHA) class II-IV were randomised to either LCZ696 200 mg twice daily or enalapril 10 mg twice daily in addition to recommended therapy, including BBs and MRAs. 16, 17 The boundary for an overwhelming benefit of LCZ696 was crossed which meant that, according to pre-specified rules, after a median follow up of 27 months, the trial was stopped early. 18 Primary outcome, which was a composite of death from cardiovascular causes or a first hospitalisation for HF, ( Figure 1A and Table 1) . 17, 19 Both components of the primary composite endpoint were reduced by Figure 1C and Table 1 ). 17, 19 LCZ696 was more efficacious than enalapril both in terms of reducing sudden cardiac deaths and reducing deaths from worsening HF; this accounted for the majority of cardiovascular deaths. 20 The LCZ696 treatment effect for sudden cardiac death was not influenced by the presence of defibrillator devices. 20 The efficacy of LCZ696 was superior to that of enalapril across the spectrum of age of the PARADIGM-HF patients, with a favourable benefit-risk profile apparent in all age groups. 21 Although most PARADIGM-HF patients had mild symptoms, many were at high risk for adverse outcomes and obtained a large absolute benefit from LCZ696, compared with enalapril. 22 In addition, in surviving patients with HF, LCZ696 prevented clinical progression more effectively than enalapril. 23 Overall, fewer patients stopped their study medication because of an adverse event in the LCZ696 group than in the enalapril group (10.7% versus 12.3%; p=0.03). 17 No major safety signals emerged for LCZ696
therapy. 18 The LCZ696 group had lower proportions of patients with renal impairment, hyperkalaemia and cough than the enalapril group, though the proportion of patients with hypotension was higher in the LCZ696 group ( Table 2) . Angioedema occurred very rarely and although it was more frequent in the LCZ696 than in the enalapril group, the study was not powered to show differences in such rare events ( 18 
